A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients.

Trial Profile

A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2011

At a glance

  • Drugs Atenolol; Hydrochlorothiazide; Valsartan
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
    • 27 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top